Frontier Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$95.1M Buy
2,847,936
+656,754
+30% +$16.3M 0.89% 19
2026
Q1
$45.9M Buy
2,191,182
+226,098
+12% +$5.09M 0.47% 66
2025
Q4
$45.2M Buy
1,965,084
+895,986
+84% +$29.5M 0.48% 67
2025
Q3
$32.2M Buy
1,069,098
+543,634
+103% +$16.3M 0.29% 128
2025
Q2
$19.1M Buy
+525,464
New +$18.9M 0.18% 188

Other funds holding RARE

Frontier Capital Management's RARE Position: Q2 2026 in Review

Frontier Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 30% in Q2 2026, buying an estimated $16.3M and bringing the position to 2,847,936 shares worth $95.1M. The position accounts for 0.89% of the portfolio, ranked #19.

Frontier Capital Management first reported a position in RARE in Q2 2025 and has held it in 5 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Frontier Capital Management held 2,847,936 shares of Ultragenyx Pharmaceutical worth $95.1M as of Q2 2026.
  • Frontier Capital Management bought 656,754 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $16.3M.
  • Ultragenyx Pharmaceutical made up 0.89% of Frontier Capital Management's portfolio in Q2 2026, its #19 holding.
  • Frontier Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 5 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.